Phlecs presents two significant clinical studies demonstrating the effectiveness of its technology in supporting patients with eczema and long COVID.
Terneuzen, the Netherlands
December 3, 2024
The Medical University of Lodz, Poland’s largest public medical university, recently conducted two studies confirming that full-body blue light therapy is a safe and effective treatment for patients with eczema and post-COVID chronic fatigue.
- Eczema study
Eczema (also known as atopic dermatitis) is a prevalent, chronic skin disorder characterized by symptoms such as dry skin, localized red scaly patches, intense itching, and skin discomfort. Its prevalence is substantial, affecting approximately 20% of children and up to 10% of adults. In the Netherlands, approximately 400,000 people have constitutional eczema, approximately 2.5% of the population. The relentless itch often leads to frequent scratching, exacerbating skin damage and perpetuating a distressing cycle known as the “itch-scratch-itch” cycle. This condition’s burden can significantly impact an individual’s physical health, mental well-being, and overall quality of life.
20 patients (age 9-45) with moderate and severe AD were included in the study. Treatment consisted of 10 irradiations with PHLECS Full Body Blue device. The results show after 10 sessions of full blue light therapy (453 nm) statistically significant improvements were observed in SCORing Atopic Dermatitis (-48%) and Itching Visual Analogue Scale (-40%). Moreover, statistically significant decrease in Dermatology Life Quality Index (DLQI) was noted (-48%). - Post-COVID study
The MIT report assumes 450,000 patients, of which 90,000 patients with serious long-term complaints. The first report of a multi-year study shows that 9 out of 10 people who have registered with C-support suffer from serious fatigue, and 1 in 4 from depressive complaints or anxiety disorders. More than 90% experience problems with performing their social roles, and 4 out of 5 people work fewer hours or are unable to work.
The clinical study comprised of 43 adults who underwent COVID-19 infection with a subjective feeling of fatigue 4 weeks after the infection. All participants underwent 10 PHLECS full-body blue light irradiation for 15 min a day for 5 consecutive days each week. All participants were assessed using the Fatigue Severity Scale (FSS), Short Form 36 Vitality Subscale (SF-36) and Dermatology Life Quality Index (DLQI).
Irradiation with blue light resulted in a significant decrease in FSS (-30%) and DLQI (-48%) as well as in an increase in SF-36 (+33%)
David Aubert, CEO, and Co-founder of Phlecs, commented on these promising results, stating, “These findings are highly encouraging, and we anticipate further studies will confirm the long-term effectiveness and safety of blue light therapy. At Phlecs, we remain dedicated to advancing our full-body blue light platform to support eczema and post-COVID patients both in the Netherlands and internationally.”
